Transporters in African trypanosomes: Role in drug action and resistance

International Journal for Parasitology

Volumn 31, Issue 5-6, 2001, Pages 512-522

  De Koning, Harry P ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Chemotherapy; Diamidine; Drug uptake; Melarsoprol; Transporter; Trypanosome; Difluoromethylornithine

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; ALLOPURINOL; ANTITRYPANOSOMAL AGENT; ARSANILIC ACID; DIAMIDINE DERIVATIVE; DIMINAZENE ACETURATE; EFLORNITHINE; ETHIDIUM; FORMYCIN; FORMYCIN B; ISOMETAMIDIUM; ISOMETAMIDIUM CHLORIDE; MELARSAMINE; MELARSENOXIDE; MELARSONYL POTASSIUM; MELARSOPROL; METHYLDOPA; METRONIDAZOLE; NIFURTIMOX; ORGANOARSENIC DERIVATIVE; ORNITHINE; PROPAMIDINE; STILBAMIDINE; TRYPARSAMIDE; TUBERCIDIN;

AFRICA; AFRICAN TRYPANOSOMIASIS; ARTICLE; DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; DRUG UPTAKE; HUMAN; NONHUMAN;

EID: 0035339852     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7519(01)00167-9     Document Type: Review

References (100)

1. Multiple drug resistant Trypanosoma congolense populations in village cattle of Metekel district, north-west Ethiopia
2. Treatment of human trypanosomiasis
3. Resistance to DL-a-difluoromethylornithine by clinical isolates to Trypanosoma brucei rhodesiense
4. The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes
5. A diamidine-resistant Trypanosoma equiperdum clone contains a P2 purine transporter with reduced substrate affinity
6. Trypanosome glucose transporters
7. Uptake of the nitroimidazole drug megazol by African trypanosomes
8. Pentamidine uptake in Leishmania donovani and Leishmania amazonensis promastigotes and amastigotes
9. Altered transport properties of pentamidine-resistant Leishmania donovani and Leishmania amazonensis promastigotes
10. Putrescine and spermidine transport in Leishmania
11. Biochemical changes associated with a-difluoromethylornithine uptake and resistance in Trypanosoma brucei
12. Properties of melarsamine hydrochloride (cymelarsan) in aqueous solution
13. Characterisation of pentamidine-resistant Trypanosoma brucei brucei
14. New therapeutic regimen for sleeping sickness. Description, results and lessons from the clinical trial established in Bwamanda (Equateur, RDC)
15. Catalytic irreversible inhibition of Trypanosoma brucei brucei ornithine decarboxylase by substrate and product analogs and their effects on murine trypanosomiasis
16. Uptake of a-difluoromethylornithine by Trypanosoma brucei brucei
17. Experimental models for new chemotherapeutic approaches to human African trypanosomiasis
18. In vitro drug sensitivity of Trypanosoma gambiense isolates
19. An in vitro bioassay for quantification of melarsoprol in serum and cerebrospinal fluid
20. Pharmacokinetic properties of the trypanocidal drug melarsoprol
21. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: A randomised trial
22. Arsenical resistant trypanosomes lack an unusual adenosine transporter
23. Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei
24. Zoonotic infections in Nigeria: Overview from a medical perspective
25. Clinical pharmacokinetics of suramin inpatients with HTLV-III/LAV infection
26. Receptor-mediated endocytosis in the bloodstream form of Trypanosoma brucei
27. Pentamidine transport and sensitivity in brucei-group trypanosomes
28. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters. Implications for cross-resistance with arsenicals
29. Hypoxanthine uptake through a purine-selective nucleobase transporter in Trypanosoma brucei brucei procyclics is driven by protonmotive force
30. Purine nucleobase transport in bloodstream forms of Trypanosoma brucei brucei is mediated by two novel transporters
31. Purine transporters in bloodstream forms of T. b. brucei: Substrate recognition motifs and affinity for trypanocidal drugs
32. Characterisation of a nucleoside/proton symporter in procyclic Trypanosoma brucei brucei
33. The uptake and mode of action of drugs against sleeping sickness
34. Free radical metabolites in the mode of action of chemotherapeutic agents and phagocytic cells on Trypanosoma cruzi
35. Free redical metabolites in the mode of action of chemotherapeutic agents and phagocytic cells on Trypanosoma cruzi
36. Drug resistance in Sudanese Trypanosoma evansi
37. Megazol combined with suramin: A chemotherapy regimen which reversed the CNS pathology in a model of human African trypanosomiasis in mice
38. Pharmacokinetics, metabolism and excretion of megazol in a Trypanosoma brucei gambiense primate model of human African trypanosomiasis
39. Uptake of a-difluoromethylornithine by mouse fibroblasts
40. Uptake of the trypanocidal drug suramin by bloodstream forms of Trypanosoma brucei and its effect on respiration and growth rate in vivo
41. Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to other drugs and trypanothione metabolism
42. A nitroimidazole-thiadiazole derivative with curative action in experimental Trypanosoma cruzi infections
43. Reduced drug accumulation in multiple drug-resistant human KB carcinoma cells
44. Mel B in the treatment of human trypanosomiasis
45. MelB in the treatment of African sleeping sickness
46. Some effects of pentamidine di-isethionate on Crithidia fasciculata
47. Concentration of Bayer 205 (Germanin) in human blood and cerebrospinal fluid after treatment
48. Rapid and regulated degradation of ornithine decarboxylase
49. Epidemiological relationships of Trypanosoma brucei stocks from South East Uganda: Evidence for different population structures in human infective and non-human infective isolates
50. The lesions produced in the central nervous system by certain organic arsenical compounds
51. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-a-difluoromethylornithine (DFMO)
52. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to DL-a-difluoromethylornithine
53. Chemotherapy of trypanosome and spirochate infections. Chemical series 1: N-phenylglycineamide-p-arsonic acid
54. Drug resistance in African trypanosomes
55. Physico-chemical properties of the trypanocidal drug melarsoprol
56. Investigations of the metabolites of the trypanocidal drug melarsoprol
57. Studies in cattle on the distribution of the anti-trypanosomal drug diminazene aceturate (®Berenil)
58. Pharmacokinetic investigations on diminazene and rolitetracycline in comparison to a combination of both
59. Current situation of African trypanosoiasis
60. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda
61. ELISA assay for melarsoprol
62. Comparative pharmacokinetics of diminazene in non-infected Boran (Bos indicus) cattle and Boran cattle infected with Trypanosoma congolense
63. Anti-proliferative properties of DL-a-difluoromethyl ornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase
64. Identification of three ABC transporter genes in Trypanosoma brucei spp
65. A nucleoside transporter from Trypanosoma brucei involved in drug resistance
66. Susceptibility of Ugandan Trypanosoma brucei rhodesiense isolated from man and animal reservoirs to diminazene, isometamidium and melarsoprol
67. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei sleeping sickness
68. Long-term occurrence of Trypanosoma congolense resistant to diminazene, isometamidium and homidium in cattle at Ghibe, Ethiopia
69. Derivation and characterisation of a quinapyramine-resistant clone of Trypanosoma congolense
70. Trypanosoma brucei infection in a sleeping sickness epidemic area of Uganda
71. Recent advances in the biochemistry of polyamines in eukaryotes
72. The treatment of human African trypanosomiasis
73. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness
74. Pharmacology of diminazene: A review
75. Cross-resistance associated with development of resistance to isometamidium in a clone of Trypanosoma congolense
76. Blood-brain barrier damage in experimental African trypanosomiasis
77. A Trypanosoma brucei mutant resistant to a-difluoromethylornithine
78. Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei: Implications for enzyme turnover and selective difluoromethylornithine inhibition
79. Induction of resistance to melarsenoxide cysteamine (MelCy) in Trypanosoma brucei brucei
80. Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by a-difluoromethylornithine. Characterisation of sequences at the inhibitor and coenzyme binding sites
81. Alteration to one of three adenosine transporters is associated with resistance to Cymelarsan in Trypanosma evansi
82. Characterisation of cloned lines of Trypanosoma brucei expressing stable resistance to MelCy and suramin
83. Trypanosoma brucei: Lack of cross-resistance to melarsoprol in vitro by cymelarsan-resistant parasites
84. Uptake of NO-releasing drugs by the P2 nucleoside transporter in trypanosomes
85. Alterations in drug transport in resistant Trypanosoma congolense
86. Reduced accumulation of isometamidium by drug-resistant Trypanosoma congolense
87. Transport of isometamidium (samorin) by drug-resistant and drug-sensitive Trypanosoma congolense
88. Comparative studies of nifurtimox uptake and metabolism by drug-resistant and susceptible strains of Trypanosoma cruzi
89. An approach to use an unusual adenosine transporter to selectively deliver polyamine analogues to trypanosomes
90. The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action
91. The determination of pentamidine (4,4′-diamidinophenoxypentane) in plasma, urine, and tissues
92. Pentamidine: Clinical pharmacologic correlations in man and mice
93. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis
94. +-dependent transporter with broad substrate selectivity
95. Modulation of mitochondrial electrical potential: A candidate mechanism for drug resistance in African trypanosomes
96. Drug resistance in trypanosomes: Effects of metabolic inhibitors, pH and oxidation-reduction potential on normal and resistant Trypanosoma rhodesiense
97. Review of chemotherapeutic and chemoprophylactic agents
98. The lipid metabolism of blood and culture forms of Trypanosoma lewisi and Trypanosoma rhodesiense
99. Blood-brain barrier transport of reduced folic acid
100. Evaluation of an arsenical compound (RM110, mel Cy, Cymelarsan®) against susceptible and drug-resistant Trypanosoma brucei brucei and T. b. evansi